Today: 19 April 2026
UOB stock slips in Singapore after JPMorgan downgrade — here’s what investors watch next
26 January 2026
1 min read

UOB stock slips in Singapore after JPMorgan downgrade — here’s what investors watch next

Singapore, Jan 26, 2026, 14:51 SGT — Regular session

  • UOB shares fell 2.7% to S$38.45 in afternoon trading, underperforming other local banks
  • JPMorgan downgraded UOB to “underweight” but left its target price steady at S$34
  • Attention shifts to UOB’s full-year results for Feb 24

United Overseas Bank Ltd (UOB) shares dropped on Monday, falling 2.66% to S$38.45 by 2:48 p.m. local time, after touching a high of S$39.20 earlier. The Straits Times Index in Singapore dipped 0.69%. DBS shares slipped 0.8%, while OCBC dropped 1.22%.

The pullback follows UOB’s record close on Friday, but selling pressure emerged after JPMorgan downgraded the stock, The Business Times reported. JPMorgan shifted its rating from “neutral” to “underweight,” signaling expectations that the stock will underperform its peers, while maintaining a target price of S$34, the report added. The Business Times

JPMorgan told The Edge Singapore it doesn’t expect asset quality concerns to be fully resolved by 4Q2025. It also ranked UOB behind DBS and OCBC in a new “pecking order.” The bank pointed to risks from commercial real estate, rising credit costs in Thailand, and tighter liquidity in Indonesia as reasons UOB’s shares could lose steam after a strong rally. The Edge Singapore

At the moment, this appears more like profit-taking disguised as something else. UOB had been a top performer among Singapore’s banks, and Monday’s dip is cutting back on those gains—though it’s far from wiping them out.

Traders are keeping an eye on whether the selling spreads across the sector. Singapore’s major lenders have been trading more in unison recently, and because UOB carries significant weight, any sharp move there can quickly impact the benchmark.

The downside scenario is clear. If loan demand weakens, funding costs hit harder than anticipated, or provisions climb once more, the stock could slide further—even without fresh headlines.

The next major trigger is coming up fast: UOB is set to report its full-year 2025 results on Feb 24, ahead of market open, according to a filing with the Singapore Exchange.

Investors will focus on any changes in comments about asset quality, updates on credit cost forecasts, and management’s stance on capital and shareholder returns.

For now, the tape speaks for itself — and if broker downgrades extend past JPMorgan, it might signal more than a brief breather after a record run, potentially marking the start of a broader reset ahead of earnings.

Stock Market Today

  • 2 TSX Stocks Under $100 with Strong Upside Potential
    April 18, 2026, 9:56 PM EDT. CES Energy (TSX:CEU) and Bird Construction are two TSX-listed stocks priced below $100 that offer significant growth potential. CES Energy provides consumable chemical solutions to oil and gas producers, benefiting from rising service intensity and demand for advanced chemical treatments. Despite softer drilling activity, CES's revenue growth remains robust, supported by its asset-light model and strategic acquisitions. Macro trends like growing global energy demand and LNG infrastructure expansion further boost its outlook. Bird Construction, also trading under $100, stands out for its presence in the construction sector, which benefits from infrastructure spending and urban development. Both companies show disciplined capital allocation and resilient revenue drivers, making them attractive for investors seeking accessible entry points and potential capital appreciation on the TSX.

Latest article

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

18 April 2026
Definium Therapeutics shares rose to $22.68 after Stifel and Piper Sandler initiated coverage with Buy ratings, citing late-stage trials of DT120, an LSD-based tablet for anxiety and depression. The company will host an investor day April 22 in New York to discuss upcoming Phase 3 data. DT120 is in four pivotal studies, with top-line results expected through 2026. Johnson & Johnson and Compass Pathways are advancing rival clinic-based psychiatric drugs.
QBE share price: ASX:QBE in focus as Australia Day shuts markets, CPI looms
Previous Story

QBE share price: ASX:QBE in focus as Australia Day shuts markets, CPI looms

Singtel stock price today: SGX:Z74 edges up as MAS policy call and telco shake-up loom
Next Story

Singtel stock price today: SGX:Z74 edges up as MAS policy call and telco shake-up loom

Go toTop